Publication
Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (10)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 10
- cancerLung Non-Small Cell Carcinomacivic_curation1.00
- drugAZD3463civic_curation1.00
- drugBrigatinibcivic_curation1.00
- drugCabozantinibcivic_curation1.00
- drugCeritinibcivic_curation1.00
- drugCrizotinibcivic_curation1.00
- drugForetinibcivic_curation1.00
- geneROS1civic_curation1.00
- variantROS1 Fusioncivic_curation1.00
- variantROS1 G2032Rcivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26372962
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ROS1 G2032R1 | ||||||||
| Crizotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Resistance | — | submitted | EID4615In an in vitro study, a Ba/F3 cell line expressing CD74-ROS1 fusion (a known sensitizing alteration to crizotinib) and a ROS1 G2032R co-mutation demonstrated resistance to crizotinib treatment (1,192 … (full text at CIViC) PMID 26372962 · Davare et al., 2015 · Open in CIViC | civic |
| ROS1 Fusion + ROS1 G2032R2 | ||||||||
| AZD3463 + Brigatinib + Ceritinib + CrizotinibSubstitutes | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | accepted | EID1250Preclinical study analyzing the efficacy of dual ROS1/ALK and more specific ROS1 inhibitors on cell lines (Ba/F3) expressing CD74-ROS1 with and without the G2032R mutation. Selective ROS1 inhibitors r… (full text at CIViC) PMID 26372962 · Davare et al., 2015 · Open in CIViC | civic |
| Cabozantinib + ForetinibSubstitutes | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1249Preclinical study analyzing the efficacy of dual ROS1/ALK and more specific ROS1 inhibitors on cell lines (Ba/F3) expressing CD74-ROS1 with and without the G2032R mutation. Selective ROS1 inhibitors r… (full text at CIViC) PMID 26372962 · Davare et al., 2015 · Open in CIViC | civic |